Related Experiment Videos
[Chronic thromboembolic pulmonary hypertension]
H Allermand1, E Toft, C J Jacobsen
1Arhus Universitetshospital, Skejby Sygehus, hjerte-, lunge- og karkirurgisk afdeling.
Ugeskrift for Laeger
|February 12, 1998
Summary
Chronic thromboembolic pulmonary hypertension (CTEPH) can lead to right-sided heart failure and high mortality. Pulmonary thrombendarterectomy significantly improves prognosis by reducing pulmonary vascular resistance.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Vascular Surgery
Context:
- Acute pulmonary hypertension carries high initial mortality.
- While some patients recanalize pulmonary arteries, others develop chronic thromboembolic pulmonary hypertension (CTEPH) due to insufficient clot resolution.
- CTEPH leads to pulmonary vascular resistance increase, right ventricular hypertrophy, and heart failure.
Purpose:
- To review the symptoms, diagnosis, and surgical treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
- To highlight the availability of pulmonary thrombendarterectomy in Denmark.
- To raise awareness of CTEPH as a treatable cause of pulmonary hypertension.
Summary:
- Untreated CTEPH has a near 100% five-year mortality.
- Pulmonary thrombendarterectomy, utilizing extracorporeal circulation and deep hypothermia, effectively lowers pulmonary vascular resistance.
- Surgical intervention significantly improves the prognosis for patients with CTEPH.
Impact:
- Pulmonary thrombendarterectomy offers a life-saving treatment option for CTEPH patients.
- Improved understanding and surgical access can reduce mortality associated with CTEPH.
- Early diagnosis and surgical intervention are crucial for better patient outcomes in CTEPH.